Business & Finance

Biopharmaceutical company reports net loss of $10.1 million in third quarter

Published in Gene Therapy Weekly, December 8th, 2005

XenoPort, Inc. (XNPT) announced its financial results for the third quarter and 9 months ended September 30, 2005 with third quarter revenues of $711,000, compared to $2.3 million for the same period in 2004.

Net loss for the third quarter was $10.1 million, compared to a net loss of $8.9 million for the same period in 2004. At September 30, 2005, XenoPort had cash and cash equivalents and short-term investments of $78.8 million.

Since the beginning of the third quarter, XenoPort has announced the following progress in its clinical-stage development programs:

- A phase IIb clinical trial demonstrated that XP13512 provided...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2005-12-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry